Accrelist Ltd · Annual Report
Chairman’s Statement
FY2020
Dear valued shareholders and partners,
Overview of FY2020
Overall, the Group’s revenue decreased by SGD 28.2 million, or 16.9%, from SGD 167.1 million in FY2019 to SGD 138.9 million in FY2020.
The decrease was mainly due to external headwinds faced by Jubilee’s Electronic Business Unit (“EBU”). EBU revenue decreased by 24.7%, or SGD 35.9 million, from SGD 145.0 million in FY2019 to SGD 109.2 million in FY2020, due to the impact of the global Covid-19 pandemic and weak global demand arising from trade tensions between the USA and China.
Within Jubilee, this was partly offset by a SGD 6.0 million increase in revenue from its Mechanical Business Unit (“MBU”). The 32.2% increase, from SGD 18.7 million in FY2019 to SGD 24.7 million in FY2020, was due to the inclusion of a full year of sales from Honfoong Plastics Industries Pte. Ltd. (“HFPL”) and a significant increase in orders from new and existing customers, as demand shifted towards Southeast Asia amid ongoing trade tensions. Jubilee’s total revenue decreased by 18.2%, from SGD 163.7 million in FY2019 to SGD 133.8 million in FY2020.
The MBU’s performance reflects the Group’s strategic involvement in Jubilee and its decision to invest in and grow the MBU segment, broadening Jubilee’s customer base and diversifying its revenue.
In this challenging environment, the Group recorded a net loss of SGD 12.9 million in FY2020, compared with a net profit of SGD 0.9 million in FY2019. The loss attributable to equity holders of SGD 12.0 million included various non-cash expenses:
- One-off remeasurement loss on financial liability of SGD 2.8 million
- Accrelist’s share of Jubilee’s loss, including non-cash expenses of SGD 1.8 million
- Amortisation of SGD 1.8 million and depreciation of SGD 2.4 million
- Impairment loss on intangible assets of SGD 1.9 million
Excluding non-cash expenses, the Group’s actual cash loss was SGD 1.3 million.
Medical aesthetics
A.M Aesthetics expanded significantly in FY2020 as the Group identified medical aesthetics as its key focus area. With the addition of its fifth clinic at Clementi Mall, the Group’s clinic network now covers almost all regions in Singapore.
Beyond Singapore, A.M Aesthetics entered into a strategic collaboration with South Korea’s Ozhean Skin and Plastic Surgery, enabling the Group to draw on the expertise of experienced practitioners. In FY2020, A.M Aesthetics opened its first two overseas clinics, in Penang and Kuala Lumpur, Malaysia.
The Group has also ventured into the distribution of medical aesthetics products through A.M Skincare to broaden its revenue stream.
Technology
The Group’s subsidiary A Tech Media Pte. Ltd. (“A Tech Media”) has moved beyond Fintech to provide services and solutions powered by facial recognition and artificial intelligence, as a systems integrator. The move reflects our ongoing efforts to identify new areas of growth.
Trade tensions and Covid-19
Technology has been at the centre of trade tensions between the USA and China, which culminated in US sanctions against Huawei and affected our Chinese customers. As their projects were delayed, demand for electronic components also declined. This significantly affected Jubilee’s EBU, as China is its largest market. However, Jubilee’s MBU was able to capture new opportunities from customers who shifted their purchasing towards the ASEAN region.
Government-imposed restrictions to curb the spread of Covid-19 also caused significant disruptions to supply chains and consumer demand worldwide, with negative effects on our business.
Investigation
Expenses incurred from longstanding practices during Chinese New Year festivities at Jubilee’s recently acquired Honfoong Plastics Industries Pte. Ltd. came under investigation by the Corrupt Practices Investigation Bureau. The expenses are not material to the Group’s financial position. We deny any wrongdoing and will continue to cooperate with the authorities. All of us at Accrelist remain committed to the principles of integrity, commitment and innovation as we work together to overcome the challenges facing the Group.
Outlook and Future Plans
Despite the impact of Covid-19, we remain confident in the long-term potential of the medical aesthetics segment. Following the easing of Covid-19 restrictions in Singapore and Malaysia, we are encouraged by the support of our customers.
We will take a measured approach to growing our network of medical aesthetics clinics sustainably. Plans are under way to set up more clinics in Johor Bahru and Ipoh, Malaysia, following the recent opening of the Group’s second clinic in Kuala Lumpur.
While the previously announced transactions had to be terminated because of the challenging business environment, we remain committed to unlocking the value of Jubilee and growing our medical aesthetics segment. The Group is exploring potential partnerships with strategic investors to help realise our vision of becoming the first medical aesthetics focused company listed on SGX.
At Jubilee, we continue to review existing processes to identify areas for cost optimisation, and will explore strategies to diversify its customer base and expand its product offerings to include higher-margin products.
We expect the impact of US-China trade tensions and the evolving Covid-19 pandemic to continue for some time. We are confident that the Group is taking the right steps to address these unprecedented challenges, and we will not lose sight of our long-term goal of delivering value for shareholders.
A Note of Appreciation
Covid-19 has disrupted many aspects of our daily lives. I am thankful for the dedication and sacrifices of our colleagues in supporting the Group’s efforts to adapt to the new normal.
I would also like to express my sincere gratitude to our shareholders and business partners for their continued support during these challenging times, as we seek to emerge stronger from this crisis.
Thank you.
Mr Terence Tea Yeok Kian
Executive Chairman and Managing Director, Accrelist Ltd